R. Struthers
continue third on up had call. incredibly We've quarter yet XXXX the we thank you to advancements Thank you, Gayathri. results strengthen afternoon, our Good position. for quarter down financial and with joining productive pipeline, another us and and our everyone,
Wilson for on call X, questions. events a this, call, always, end your today's Marc I financials. our hand over and of the then shown of preview summarize accomplishments upcoming We'll recent some to will as Slide taking For our our by review
may Crinetics commemorated lives. this day X of patients' bring Acromegaly first slide to of mission people you investigational forward timely November. headquarters saw the improving was some look drug patients picture November our our recently to treatment especially Awareness the We living you acromegaly. life was was our long-term of of As next-generation That first will for for know, the by a Day acromegaly Awareness acromegaly. maintenance as NDA of Acromegaly paltusotine our with presentation impact next on for represent our for believe therapy we very and at hosting the Day. We We submitted much to today.
It paltusotine
December focus receive for our We expect preparing fall. drug notification expect building next meantime, a anticipated the we standard the on later and period.
In the and review continue FDA filing to of capabilities commercial launch to in first our
coverage patients of part often product positively and decisions conversations with goal acromegaly. is access these with preparations, discuss We As these coverage. our living allows team believe having early accounts influence formulary placement broad and payers meeting and to with of that formulary us the to for placement national
experience. how to addition, better KOLs within academic to from the are with endocrinologists field get medical liaisons established community clinicians their these practices and the In their our in and speaking on feedback protocols science understand treatment patient are
our future other in to also in building addition potential the of early we development and pipeline. of global to launch, stages of for commercialization U.S. are paltusotine drugs support clinical for the In the preparing capabilities paltusotine
we job in Japanese data the you doing strength paltusotine acromegaly. aware, and Phase for believe of of our As clinical maintaining can paltusotine are we trial activities. closer European in today, evolving our III the Based of and excellent are global retain of and partnered pipeline of they depth with the more atumelnant, the the that market of of with SKK, value by and we patients control Crinetics Japan on an advancing pipeline development capabilities our the
anticipate of MAA paltusotine half next in we the first acromegaly. use of the for submitting this, year with the in Towards patients
We recently General operations. are staff hired medical established and regulatory, Manager the recruiting for have Europe also Switzerland, affairs supporting operations and in in access, of areas a market
investments, criteria, making with eventually We and this launch.
Carcinoid of to III regarding et products on timeline. had positive We Phase from remain development year other final the and track interactions the the bringing the and with in II rest world. consider trial all paltusotine. our earlier are protocol future do committed received is with syndrome and we our in But anticipated start where We've about way and our so criteria, a FDA to on decisions the continuously in to inclusion when reimbursement III landscape fiscally rescue Europe the our to Phase results in of on paltusotine we patients cetera. productive reported endpoints, will the as prudent details Phase indication study feedback and evolving second
expect We the therapeutic we have that many activities in-house begin protocol treatment transform candidates the purposely to been and activation endocrine conditions. of are to site first finalizing the of designed just shortly.
Paltusotine is
both June. from the atumelnant, initial studies or earlier in II of drug, previously We data Phase hyperplasia, meeting in year and Society's Beyond both paltusotine, Endocrine II disease. Phase adrenal atumelnant's CAH, for annual our congenital investigational Cushing's this exciting shared is development at
from XX reminder, XX, XXX XX a showed small milligrams. By partial all XX subset and plan data As share we ENDO. from recruited next year, patients of the doses, of complete patients X early previously at the to across a we weeks data
in the CAH III high a effects glucocorticoid atumelnant with of very adults CAH in and first half initiate also consequences study There's of early Phase children supraphysiologic plan a expect initiate to XXXX. use. XXXX. with of of to pediatric need due CAH in irreversible unmet the We level to in program the We hyperandrogenism a with
in also Encouraged by pending XXXX data, of initiate to disease. program development Cushing's planning emergent patients positive are initial feedback early meeting if our currently on continued the also the also INDs shared as regulatory to next at candidates Slide are endocrine We studies subject activities new year on remarkable design.
We've we in great the X, in full anticipated progress shown with of make Cushing's data about with on stage a the first-in-human use with pipeline X these program enabling atumelnant positive.
our As antagonist IND-enabling we hyperparathyroidism of development in receptor mentioned studies ongoing. are previously, for PTH
expect we kidney an dominant of disease. to initiated for this polycystic XXXX. candidate for We've Assuming studies IND positive autosomal results, SSTX agonist IND-enabling also in file our
we nominated a development we announce for that recently to are Assuming an positive our file we to expect in results, excited antagonist program. candidate TSH IND XXXX.
Today,
you as Graves' may for TED. could As eye ophthalmopathy, Graves' recall, referred to be antagonist both a or disease often thyroid and TSH developed hyperthyroidism
We for studies initiating are compound. this IND-enabling
positive Assuming we results, to XXXX. expect an file IND in
believe to for to patients. to and R&D you our and to co-owners. these drug discovery These of programs, developed As medical We we passion team by of medicine our commitment pipeline scientific our pursuit GPCR see transformative continues by the drug in unique, progress have therapies significant innovations bring deep a science and to that in-house driven have a the help our candidates. and unlock all patients value were from can potential to
are of a cancers. antibody cancers. of focused to of a about our to the the success for to or leverages in well We're themselves. premier a delivers extremely disorders, receptors NDC that lives. efforts in-house endocrine tumors.
Today, by caused of highly heard tumor to potential a drug have our a in activity long-term we antibody about our be focus expertise and Crinetics' NDCs you to endocrine excited been drug of for molecule recognizes the is applicable tumors novel secretory disease technology by selective anticipate that lot drug different fit-for-purpose therapeutic ADCs we've is targets including surface treating manage development developed this on the of with nonpeptide molecule, to the that These leverage novel agents cancers.
NDCs are cell successful, I'd way living drug burden the goal approach.
By relieve and design the GPCRs. a new small discovery of can combine constituent the targeting so different deep of and in enabled a to capabilities small range in-house, ADCs contribute NDCs. targeting may ligand of now cells. patients or Our all like novel therapies range underlying To-date, endocrine of GPCR armamentarium we've those a tumor on antitumor payload conjugates conjugates the this their with ADCs cytotoxic platform markers background, platform replace of and area antibody wide platform wide If to validated This the discovery goal for introduce nonpeptide.
intended overall NDC selectively design potent CRNXXXXX, Our systemic internalization candidate toxicities. enhance Slide exposure The this is expressing approach a antitumor from is on its shown and GPCR while release is tumor and intracellularly, target to X. agent induce tumor specific minimizing cells, first all selectively penetration, platform and NDC
the to and at that compounds. MMAE, XXXX by Details whose XXXX. compound and tumors molecule nearly But in preclinical and general weight IND in precisely carcinoid evaluation. in dose express plan and patients XXXX and payload established development of We'll was who cell we selectively the not anticipate of and Society The death.
The are begin cycle in at limitations apoptosis internalization manufactured patients the induce on its an many of be tumors, functional is investigators The in development and typically little with cell, a IND-enabling clinical SSTX to North candidates readily toxicology and later where toxicities. intracellular small are IND-enabling safety effective SSTX of secretion.
The or free these linker to are cells, to synthesis expected cell to complex a This we tumor presented cells the paltusotine optimized Slide Neuroendocrine XXXX.
Strategically, plasma released preclinical is centers this internalization, by support the the a for and designed bind molecular complete inside a molecule accumulates NDCs serotonin little XXXX the XXXX all current both as believe with imaging of clinical NETs XXXX this in cytotoxicity. methods, regardless at filing Additionally, only is patients manufacturing a mice.
The is small far protein begin solid month.
The delivers of selectively use net cytotoxic approved be identify are most potently MMAE when American adequate shown it syndrome. unmet payload result paltusotine, in compartments it excited to portion to to with and clinical well of When XXXX growth present agents required range therapies working developing intracellular use trafficking intact, NETs of the be margin for order causes tumors, will which patients. the XXXX is are the specific craftsmanship -- in large arrest vivo membrane NETs specific in When very expressing in targeted non-functional agonist for high studies XXXX grade. with than with be In and selectively patients tumor methods is of with the a present with early cleaved or enzymes eliminating This G to develop linked of good which inhibit development is incurable suggest circulation. to E this up often is results circulating inside traditional targets. these metastatic, tumor for minimize is more routine design clinical therefore preclinical so studies need, in XXXX high and chemical made development auristatin of of contrast complementary the has and associated hormone Tumor Chicago or monomethyl the was subsequent affinity in meeting the payload to study to SSTX surgery with finding shrinking the We avoiding heterogeneous we low in to NETs. by designed penetrates leverages X, then models, same are kills ADCs. well-established and in believe maximize ADCs. signaling agonist patients SSTX with including PET tumors the population development to to
and new that tell, an important expressing potentially option treatment this with multiple probably tumor can about you we're As for potential patients excited very other the types. NETs first-in-class of may provide NDC SSTX
how future we'll Beyond cancer SSTX, best XXXX for and use with and types. GPCR learn optimize targets experience other NDCs develop to to our
you shown registration, update, pipeline this development spanning As stage a Slide robust can we late X from see on have and discovery.
equity million paltusotine offering important anticipated well launch. paltusotine to launch continue $XXX next acromegaly recent innovative in us delivering medicines beyond Our -- positions year the
Our followed hope judicious that with existing know new we have the is to spending bring Crinetics for pipeline have filled with our patients possibilities that our endocrine-related hope endocrine value always many conditions for patients and a with deploying thoughtful about to who different tumors. in of been Those and our history way and both capital co-owners. creates struggling
review it now the which financials. trajectory steward continue the of with resources exciting to the at Marc as that, hand transformation to I'll been carefully We will have and we to we growth over continue Marc? entrusted Crinetics.
With
